Differential response by adolescents to naproxen sodium therapy for spasmodic and congestive dysmenorrhea

M. Susan Jay, Robert H. Durant, Tamsen Shoffitt, Charles W. Linder

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of this study was to determine whether adolescents with "spasmodic" dysmenorrhea (SD) versus "congestive" dysmenorrhea (CD) respond differently to naproxen sodium therapy. Forty-five females ages 12-18 years were pretested and randomly assigned in a double-blind fashion to one of five treatment regimens of various dosages of naproxen sodium and placebo. Subjects were posttested at one, two, and three months. Subjects with initial Menstrual Symptom Questionnaire (MSQ) scores of >- 76 were classified as SD (n=28) and those with scores of <-75 were classified as CD (n=17). Subjects with SD had a significant (p≤0.05) reduction in MSQ scores after the first month of naproxen sodium therapy. By the second month, the degree of reduction was associated with a loading dose of 550 mg of naproxen sodium. Subjects with CD had a dose-related (p≤0.05) response to naproxen sodium therapy that appeared to be influenced by other factors. At the first month follow-up, greater post menarchal age and parents' education were associated with increased symptom relief following naproxen sodium therapy (p≤0.05). At the second month, CD subjects with increased life crisis events and lower self-concepts had more severe symptoms following naproxen sodium therapy (p<0.05). Our subjects with SD symptoms had a greater response to naproxen sodium therapy than those with CD symptoms.

Original languageEnglish (US)
Pages (from-to)395-400
Number of pages6
JournalJournal of Adolescent Health Care
Volume7
Issue number6
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Dysmenorrhea
Naproxen
Therapeutics
Self Concept
Parents
Placebos
Education

Keywords

  • Dysmenorrhea, congestive
  • Dysmenorrhea, spasmodic
  • Naproxen sodium therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Public Health, Environmental and Occupational Health

Cite this

Differential response by adolescents to naproxen sodium therapy for spasmodic and congestive dysmenorrhea. / Jay, M. Susan; Durant, Robert H.; Shoffitt, Tamsen; Linder, Charles W.

In: Journal of Adolescent Health Care, Vol. 7, No. 6, 01.01.1986, p. 395-400.

Research output: Contribution to journalArticle

Jay, M. Susan ; Durant, Robert H. ; Shoffitt, Tamsen ; Linder, Charles W. / Differential response by adolescents to naproxen sodium therapy for spasmodic and congestive dysmenorrhea. In: Journal of Adolescent Health Care. 1986 ; Vol. 7, No. 6. pp. 395-400.
@article{ee82ccd35e2a4ec9b85082b487ae7768,
title = "Differential response by adolescents to naproxen sodium therapy for spasmodic and congestive dysmenorrhea",
abstract = "The purpose of this study was to determine whether adolescents with {"}spasmodic{"} dysmenorrhea (SD) versus {"}congestive{"} dysmenorrhea (CD) respond differently to naproxen sodium therapy. Forty-five females ages 12-18 years were pretested and randomly assigned in a double-blind fashion to one of five treatment regimens of various dosages of naproxen sodium and placebo. Subjects were posttested at one, two, and three months. Subjects with initial Menstrual Symptom Questionnaire (MSQ) scores of >- 76 were classified as SD (n=28) and those with scores of <-75 were classified as CD (n=17). Subjects with SD had a significant (p≤0.05) reduction in MSQ scores after the first month of naproxen sodium therapy. By the second month, the degree of reduction was associated with a loading dose of 550 mg of naproxen sodium. Subjects with CD had a dose-related (p≤0.05) response to naproxen sodium therapy that appeared to be influenced by other factors. At the first month follow-up, greater post menarchal age and parents' education were associated with increased symptom relief following naproxen sodium therapy (p≤0.05). At the second month, CD subjects with increased life crisis events and lower self-concepts had more severe symptoms following naproxen sodium therapy (p<0.05). Our subjects with SD symptoms had a greater response to naproxen sodium therapy than those with CD symptoms.",
keywords = "Dysmenorrhea, congestive, Dysmenorrhea, spasmodic, Naproxen sodium therapy",
author = "Jay, {M. Susan} and Durant, {Robert H.} and Tamsen Shoffitt and Linder, {Charles W.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1016/S0197-0070(86)80241-8",
language = "English (US)",
volume = "7",
pages = "395--400",
journal = "Journal of Adolescent Health",
issn = "1054-139X",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Differential response by adolescents to naproxen sodium therapy for spasmodic and congestive dysmenorrhea

AU - Jay, M. Susan

AU - Durant, Robert H.

AU - Shoffitt, Tamsen

AU - Linder, Charles W.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The purpose of this study was to determine whether adolescents with "spasmodic" dysmenorrhea (SD) versus "congestive" dysmenorrhea (CD) respond differently to naproxen sodium therapy. Forty-five females ages 12-18 years were pretested and randomly assigned in a double-blind fashion to one of five treatment regimens of various dosages of naproxen sodium and placebo. Subjects were posttested at one, two, and three months. Subjects with initial Menstrual Symptom Questionnaire (MSQ) scores of >- 76 were classified as SD (n=28) and those with scores of <-75 were classified as CD (n=17). Subjects with SD had a significant (p≤0.05) reduction in MSQ scores after the first month of naproxen sodium therapy. By the second month, the degree of reduction was associated with a loading dose of 550 mg of naproxen sodium. Subjects with CD had a dose-related (p≤0.05) response to naproxen sodium therapy that appeared to be influenced by other factors. At the first month follow-up, greater post menarchal age and parents' education were associated with increased symptom relief following naproxen sodium therapy (p≤0.05). At the second month, CD subjects with increased life crisis events and lower self-concepts had more severe symptoms following naproxen sodium therapy (p<0.05). Our subjects with SD symptoms had a greater response to naproxen sodium therapy than those with CD symptoms.

AB - The purpose of this study was to determine whether adolescents with "spasmodic" dysmenorrhea (SD) versus "congestive" dysmenorrhea (CD) respond differently to naproxen sodium therapy. Forty-five females ages 12-18 years were pretested and randomly assigned in a double-blind fashion to one of five treatment regimens of various dosages of naproxen sodium and placebo. Subjects were posttested at one, two, and three months. Subjects with initial Menstrual Symptom Questionnaire (MSQ) scores of >- 76 were classified as SD (n=28) and those with scores of <-75 were classified as CD (n=17). Subjects with SD had a significant (p≤0.05) reduction in MSQ scores after the first month of naproxen sodium therapy. By the second month, the degree of reduction was associated with a loading dose of 550 mg of naproxen sodium. Subjects with CD had a dose-related (p≤0.05) response to naproxen sodium therapy that appeared to be influenced by other factors. At the first month follow-up, greater post menarchal age and parents' education were associated with increased symptom relief following naproxen sodium therapy (p≤0.05). At the second month, CD subjects with increased life crisis events and lower self-concepts had more severe symptoms following naproxen sodium therapy (p<0.05). Our subjects with SD symptoms had a greater response to naproxen sodium therapy than those with CD symptoms.

KW - Dysmenorrhea, congestive

KW - Dysmenorrhea, spasmodic

KW - Naproxen sodium therapy

UR - http://www.scopus.com/inward/record.url?scp=0022996845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022996845&partnerID=8YFLogxK

U2 - 10.1016/S0197-0070(86)80241-8

DO - 10.1016/S0197-0070(86)80241-8

M3 - Article

VL - 7

SP - 395

EP - 400

JO - Journal of Adolescent Health

JF - Journal of Adolescent Health

SN - 1054-139X

IS - 6

ER -